Stoke Therapeutics is a single-asset biotechnology company with zorevunersen as its only pipeline candidate, offering a high-risk binary outcome; analyst consensus sees roughly 50% upside but quality metrics are critically weak and 19% short interest reflects market skepticism.
Thesis pillars
- Single Asset Pipeline Risk→Stable
- Critical Quality Shortfall↑Improving
- High Short Interest Overhang→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 16, 2026· older than 90 days
Stoke Therapeutics, Inc. (STOK) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $26.99: Concentration risk — Pipeline: zorevunersen (STK-001); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3).
Stoke Therapeutics is a late-stage clinical company developing antisense oligonucleotides using its proprietary TANGO platform, with lead candidate zorevunersen (STK-001) in a global Phase 3 trial (EMPEROR) for Dravet syndrome initiated May 2025. The company generates no product... Read more
Sell if holding. Multiple concerning factors at $26.99: Concentration risk — Pipeline: zorevunersen (STK-001); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 73. Score 5.0/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, earnings proximity 131d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA) and SEC filing concern. Suitability: speculative.
About Stoke Therapeutics, Inc.
About Stoke Therapeutics, Inc.
Stoke Therapeutics dosed the first patient in the global Phase 3 EMPEROR study for zorevunersen (STK-001) in August 2025, targeting pivotal data in mid-2027 to support a rolling NDA submission. Dravet syndrome affects an estimated 38,000 patients across the US, UK, France, Germany, Italy, Spain, and Japan, and no approved disease-modifying therapy currently exists. A second program, STK-002 for autosomal dominant optic atrophy (ADOA), dosed its first patient in the Phase 1 OSPREY study in February 2026. Stoke currently generates no product revenue.
Stoke's revenue model depends entirely on eventual commercialization of zorevunersen or future product candidates. The company has invested substantially all its financial resources in its TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which designs antisense oligonucleotides to selectively restore protein levels in haploinsufficiency diseases. Zorevunersen targets Dravet syndrome by upregulating Nav1.1 protein expression via the non-mutant copy of the SCN1A gene — an approach supported by Breakthrough Therapy Designation granted by the FDA in December 2024. The EMPEROR study enrolls approximately 150 patients aged 2 to under 18 at roughly 60 sites across the UK, US, EU, and Japan in a randomized, double-blind, sham-controlled design. Stoke retains North American commercialization rights while Biogen holds global rights outside the US, Canada, and Mexico. Manufacturing of drug substance relies on third-party contract manufacturing organizations, and the 10-K identifies the adequacy of CMO facilities as a condition of regulatory approval.
Show full overview
The mid-2027 data readout from EMPEROR is a binary event for Stoke Therapeutics: substantially all financial resources are committed to zorevunersen, the company carries no product revenue, and a rolling NDA submission in the first half of 2027 depends on positive Phase 3 results. The FDA previously placed a partial clinical hold on certain zorevunersen doses pending additional preclinical testing — subsequently lifted — demonstrating that clinical hold risk remains an active pathway risk for a single-asset program. Enrollment completion is targeted for Q2 2026; any delay extends the data timeline beyond mid-2027.
See also: Healthcare · Biotechnology
From Stoke Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Stoke Therapeutics, Inc.
Latest news
- NEWS Stoke Therapeutics to Present at Upcoming Investor Conferences in November — fiscal.ai Nov 3, 2026 neutral
- NEWS Stoke Therapeutics Q3 2026 Earnings Call Transcript — benzinga Oct 29, 2026 neutral
- NEWS Stoke Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai Oct 29, 2026
- NEWS Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate — benzinga Oct 29, 2026 neutral
- NEWS Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates — fiscal.ai Oct 22, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T12:04:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezorevunersen (STK-001)10-K Item 1A: 'We have invested substantially all of our efforts and financial resources in the development of TANGO and our current lead product candidate, zorevunersen'
Material Events(8-K, last 90d)
- 2026-03-27Item 4.01HIGHStoke dismissed KPMG LLP as independent auditor on March 23, 2026. No disagreements with KPMG; prior-year reports were unqualified with no reportable events. New independent registered public accounting firm appointed (name truncated in filing body).SEC filing →
- 2026-04-07Item 5.02LOWBoard expanded to 10 directors; G. Clare Kahn, Ph.D. appointed as Class I director effective April 3, 2026. Also appointed to Nominating and Corporate Governance Committee and as chairperson of the R&D Committee. No successor named for any departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $26.99: Concentration risk — Pipeline: zorevunersen (STK-001); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 73. Prior stop was $25.10. Score 5.0/10, moderate confidence.
Analyst target: $40.35 (+49.5% upside). Prior stop was $25.10. Stop-loss: $25.10.
Concentration risk — Pipeline: zorevunersen (STK-001); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3); Consecutive earnings misses (3).
Stoke Therapeutics, Inc. trades at a P/E of N/A (forward -7.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts rate STOK, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $46.
What does Stoke Therapeutics, Inc. do?Stoke Therapeutics is a late-stage clinical company developing antisense oligonucleotides using its proprietary TANGO...
Stoke Therapeutics is a late-stage clinical company developing antisense oligonucleotides using its proprietary TANGO platform, with lead candidate zorevunersen (STK-001) in a global Phase 3 trial (EMPEROR) for Dravet syndrome initiated May 2025. The company generates no product revenue and collaborates with Biogen for commercialization of zorevunersen outside the US, Canada, and Mexico.